Devang R. Amin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Devang R. Amin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Alexis Tumolo
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publicationAmber Khanna
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publication- Andres Felipe Henao-Martinez
Division of Infectious Diseases, University of Colorado , Aurora, Colorado
1 shared publication - Brisa Peña
Department of Bioengineering, University of Colorado Denver, Aurora, USA
1 shared publication Daniel W. Groves
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publication- Eric Sink
Department of Internal Medicine, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA
1 shared publication
Latest Publications
- 25 December 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 567-568
Postoperative heartbreak: Takotsubo cardiomyopathy following liver transplantation
An abstract is unavailable. This article is available as a PDF only.
- 25 December 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (5) , 567-568
Postoperative heartbreak: Takotsubo cardiomyopathy following liver transplantation
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 5 December 2022
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 9
Sustained monomorphic ventricular tachycardia as the presenting sign of Chagas’ cardiomyopathy in a low prevalence setting, diagnosis and management challenges. A case report
Approximately 300,000 people in the United States are estimated to have Chagas’ disease, with cardiac manifestations including arrhythmias occurring in 20%–30% of patients. We report a patient diagnosed with Chagas’ cardiomyopathy after presenting in ventricular tachycardia. This patient was asymptomatic before her presentation with recurrent episodes of ventricular tachycardia, which motivated us to screen her since she was an immigrant from an endemic Chagas region. This manuscript highlights some of the characteristic cardiac magnetic resonance imaging (MRI) and electrophysiology findings present in patients with Chagas’ cardiomyopathy. We also detail the management of patients with Chagas’ cardiomyopathy who have suffered from ventricular tachycardia.
- 5 December 2022
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 9
Open AccessSustained monomorphic ventricular tachycardia as the presenting sign of Chagas’ cardiomyopathy in a low prevalence setting, diagnosis and management challenges. A case report
Approximately 300,000 people in the United States are estimated to have Chagas’ disease, with cardiac manifestations including arrhythmias occurring in 20%–30% of patients. We report a patient diagnosed with Chagas’ cardiomyopathy after presenting in ventricular tachycardia. This patient was asymptomatic before her presentation with recurrent episodes of ventricular tachycardia, which motivated us to screen her since she was an immigrant from an endemic Chagas region. This manuscript highlights some of the characteristic cardiac magnetic resonance imaging (MRI) and electrophysiology findings present in patients with Chagas’ cardiomyopathy. We also detail the management of patients with Chagas’ cardiomyopathy who have suffered from ventricular tachycardia.
- Open Access
Nanomaterials for Cardiac Tissue Engineering
End stage heart failure is a major cause of death in the US. At present, organ transplant and left-ventricular assist devices remain the only viable treatments for these patients. Cardiac tissue engineering presents the possibility of a new option. Nanomaterials such as gold nanorods (AuNRs) and carbon nanotubes (CNTs) present unique properties that are beneficial for cardiac tissue engineering approaches. In particular, these nanomaterials can modulate electrical conductivity, hardness, and roughness of bulk materials to improve tissue functionality. Moreover, they can deliver bioactive cargo to affect cell phenotypes. This review covers recent advances in the use of nanomaterials for cardiac tissue engineering.
Open AccessNanomaterials for Cardiac Tissue Engineering
End stage heart failure is a major cause of death in the US. At present, organ transplant and left-ventricular assist devices remain the only viable treatments for these patients. Cardiac tissue engineering presents the possibility of a new option. Nanomaterials such as gold nanorods (AuNRs) and carbon nanotubes (CNTs) present unique properties that are beneficial for cardiac tissue engineering approaches. In particular, these nanomaterials can modulate electrical conductivity, hardness, and roughness of bulk materials to improve tissue functionality. Moreover, they can deliver bioactive cargo to affect cell phenotypes. This review covers recent advances in the use of nanomaterials for cardiac tissue engineering.